Research ExplorerPublicationsHuman kallikrein 13 protein in ovarian cancer cytosols: a ne...

Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker

Standard

Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. / Scorilas, Andreas; Borgoño, Carla A; Harbeck, Nadia; Dorn, Julia; Schmalfeldt, Barbara; Schmitt, Manfred; Diamandis, Eleftherios P.

In: J CLIN ONCOL, Vol. 22, No. 4, 15.02.2004, p. 678-85.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Scorilas, A, Borgoño, CA, Harbeck, N, Dorn, J, Schmalfeldt, B, Schmitt, M & Diamandis, EP 2004, 'Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker', J CLIN ONCOL, vol. 22, no. 4, pp. 678-85. https://doi.org/10.1200/JCO.2004.05.144

APA

Scorilas, A., Borgoño, C. A., Harbeck, N., Dorn, J., Schmalfeldt, B., Schmitt, M., & Diamandis, E. P. (2004). Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J CLIN ONCOL, 22(4), 678-85. https://doi.org/10.1200/JCO.2004.05.144

Vancouver

Scorilas A, Borgoño CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M et al. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J CLIN ONCOL. 2004 Feb 15;22(4):678-85. https://doi.org/10.1200/JCO.2004.05.144

Bibtex

@article{7a7cf19db6d749cebdf1ea98f1fc497f,
title = "Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker",
abstract = "PURPOSE: Human kallikrein 13 (hK13; encoded by the KLK13 gene) is a secreted serine protease expressed in endocrine tissues, including the prostate, testis, breast, and ovary. We have previously reported steroid hormone regulation of the KLK13 gene and its clinical value as a marker of favorable prognosis in breast cancer at the mRNA level. We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas.PATIENTS AND METHODS: Using a newly developed enzyme-linked immunosorbent assay (ELISA), hK13 levels were quantified in 131 ovarian tumor extracts and correlated with various clinicopathological variables and outcome (progression-free survival [PFS], overall survival [OS]), over a median follow-up period of 42 months.RESULTS: hK13 concentration in ovarian tumor cytosols ranged from 0 to 18.4 ng/mg of total protein. An optimal cutoff value of 0.13 ng/mg (67(th) percentile) was selected, based on the ability of hK13 values to predict the PFS of the study population, to categorize tumors as hK13-positive or negative. Women with hK13-positive tumors most often had early stage (stage I/II) disease, no residual tumor after surgery and optimal debulking success (P <.05). Univariate and multivariate Cox regression analyses revealed that patients with hK13-positive tumors had a significantly longer PFS and OS than hK13-negative patients (P <.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK13-positive tumors (P =.007 and P =.002, respectively).CONCLUSION: These results indicate that hK13 is an independent marker of favorable prognosis in ovarian cancer.",
keywords = "Adult, Aged, Aged, 80 and over, Cytosol, Disease-Free Survival, Female, Humans, Kallikreins, Middle Aged, Multivariate Analysis, Ovarian Neoplasms, Proportional Hazards Models, Survival Rate, Tumor Markers, Biological",
author = "Andreas Scorilas and Borgo{\~n}o, {Carla A} and Nadia Harbeck and Julia Dorn and Barbara Schmalfeldt and Manfred Schmitt and Diamandis, {Eleftherios P}",
year = "2004",
month = feb,
day = "15",
doi = "10.1200/JCO.2004.05.144",
language = "English",
volume = "22",
pages = "678--85",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

RIS

TY - JOUR

T1 - Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker

AU - Scorilas, Andreas

AU - Borgoño, Carla A

AU - Harbeck, Nadia

AU - Dorn, Julia

AU - Schmalfeldt, Barbara

AU - Schmitt, Manfred

AU - Diamandis, Eleftherios P

PY - 2004/2/15

Y1 - 2004/2/15

N2 - PURPOSE: Human kallikrein 13 (hK13; encoded by the KLK13 gene) is a secreted serine protease expressed in endocrine tissues, including the prostate, testis, breast, and ovary. We have previously reported steroid hormone regulation of the KLK13 gene and its clinical value as a marker of favorable prognosis in breast cancer at the mRNA level. We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas.PATIENTS AND METHODS: Using a newly developed enzyme-linked immunosorbent assay (ELISA), hK13 levels were quantified in 131 ovarian tumor extracts and correlated with various clinicopathological variables and outcome (progression-free survival [PFS], overall survival [OS]), over a median follow-up period of 42 months.RESULTS: hK13 concentration in ovarian tumor cytosols ranged from 0 to 18.4 ng/mg of total protein. An optimal cutoff value of 0.13 ng/mg (67(th) percentile) was selected, based on the ability of hK13 values to predict the PFS of the study population, to categorize tumors as hK13-positive or negative. Women with hK13-positive tumors most often had early stage (stage I/II) disease, no residual tumor after surgery and optimal debulking success (P <.05). Univariate and multivariate Cox regression analyses revealed that patients with hK13-positive tumors had a significantly longer PFS and OS than hK13-negative patients (P <.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK13-positive tumors (P =.007 and P =.002, respectively).CONCLUSION: These results indicate that hK13 is an independent marker of favorable prognosis in ovarian cancer.

AB - PURPOSE: Human kallikrein 13 (hK13; encoded by the KLK13 gene) is a secreted serine protease expressed in endocrine tissues, including the prostate, testis, breast, and ovary. We have previously reported steroid hormone regulation of the KLK13 gene and its clinical value as a marker of favorable prognosis in breast cancer at the mRNA level. We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas.PATIENTS AND METHODS: Using a newly developed enzyme-linked immunosorbent assay (ELISA), hK13 levels were quantified in 131 ovarian tumor extracts and correlated with various clinicopathological variables and outcome (progression-free survival [PFS], overall survival [OS]), over a median follow-up period of 42 months.RESULTS: hK13 concentration in ovarian tumor cytosols ranged from 0 to 18.4 ng/mg of total protein. An optimal cutoff value of 0.13 ng/mg (67(th) percentile) was selected, based on the ability of hK13 values to predict the PFS of the study population, to categorize tumors as hK13-positive or negative. Women with hK13-positive tumors most often had early stage (stage I/II) disease, no residual tumor after surgery and optimal debulking success (P <.05). Univariate and multivariate Cox regression analyses revealed that patients with hK13-positive tumors had a significantly longer PFS and OS than hK13-negative patients (P <.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK13-positive tumors (P =.007 and P =.002, respectively).CONCLUSION: These results indicate that hK13 is an independent marker of favorable prognosis in ovarian cancer.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Cytosol

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Kallikreins

KW - Middle Aged

KW - Multivariate Analysis

KW - Ovarian Neoplasms

KW - Proportional Hazards Models

KW - Survival Rate

KW - Tumor Markers, Biological

U2 - 10.1200/JCO.2004.05.144

DO - 10.1200/JCO.2004.05.144

M3 - SCORING: Journal article

C2 - 14966091

VL - 22

SP - 678

EP - 685

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 4

ER -